How has been the historical performance of Senores Pharma.?

Answer:The historical performance of Senores Pharma shows significant growth in various financial metrics from March 2024 to March 2025.

Breakdown:
In the fiscal year ending March 2025, Senores Pharma reported net sales of 398.25 Cr, a substantial increase from 214.52 Cr in the previous year. Total operating income mirrored this growth, reaching 398.25 Cr compared to 214.52 Cr in March 2024. The company's total expenditure also rose to 308.55 Cr from 172.92 Cr, driven by higher raw material costs and employee expenses. Operating profit (PBDIT) increased to 108.96 Cr from 44.42 Cr, reflecting improved operational efficiency, while profit before tax surged to 70.57 Cr from 24.95 Cr. Consequently, profit after tax rose to 58.34 Cr, up from 32.71 Cr, resulting in a net profit of 58.56 Cr compared to 31.45 Cr the previous year. The earnings per share (EPS) improved to 12.72 from 10.31, indicating enhanced shareholder value. On the balance sheet, total liabilities increased to 606.92 Cr from 131.05 Cr, with total debt rising to 248.38 Cr. However, total assets also grew significantly to 606.92 Cr from 131.05 Cr, showcasing the company's expansion. Cash flow from financing activities was positive at 86.00 Cr, contributing to a net cash inflow of 12.00 Cr, compared to a net outflow of 3.00 Cr in the prior year. Overall, Senores Pharma demonstrated robust growth across key financial metrics, indicating a strong upward trajectory in its performance.